tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Optimistic Buy Rating for Passage Bio’s PBFT02: Promising Efficacy and Managed Safety Concerns
PremiumRatingsOptimistic Buy Rating for Passage Bio’s PBFT02: Promising Efficacy and Managed Safety Concerns
1M ago
Passage Bio’s Promising Clinical Trial Results and Strategic Adjustments Justify Buy Rating
Premium
Ratings
Passage Bio’s Promising Clinical Trial Results and Strategic Adjustments Justify Buy Rating
1M ago
Passage Bio Releases Promising Interim Data for PBFT02
Premium
Company Announcements
Passage Bio Releases Promising Interim Data for PBFT02
1M ago
Passage Bio’s Strategic Positioning and Growth Potential: A Buy Rating Analysis
PremiumRatingsPassage Bio’s Strategic Positioning and Growth Potential: A Buy Rating Analysis
3M ago
Passage Bio: Steady Progress and Financial Stability Reinforce Buy Rating with $13 Target
Premium
Ratings
Passage Bio: Steady Progress and Financial Stability Reinforce Buy Rating with $13 Target
3M ago
Passage Bio Reports Q1 2025 Financial Results
Premium
Company Announcements
Passage Bio Reports Q1 2025 Financial Results
3M ago
Passage Bio price target lowered to $6 from $7 at Chardan
PremiumThe FlyPassage Bio price target lowered to $6 from $7 at Chardan
5M ago
Passage Bio: Promising Clinical Progress and Strong Financial Health Support Buy Rating
Premium
Ratings
Passage Bio: Promising Clinical Progress and Strong Financial Health Support Buy Rating
5M ago
Passage Bio Reports 2024 Financial Results and Program Advances
Premium
Company Announcements
Passage Bio Reports 2024 Financial Results and Program Advances
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100